Table 1:

Comparison of Pre and post-Bristol Stool Scale outpatient cohorts

	Prior Cohort without BSS (N=114)	Cohort with BSS included (N=112)	P value
Age	61.0±6.01	62.3±12.2	0.57
Male sex	103 (90%)	98 (88%)	0.49
MELD score	12.6±5.6	12.3±5.4	0.30
Ascites	52 (46%)	49 (44%)	0.77
Prior HE	50 (44%)	56 (50%)	0.36
Lactulose	50 (44%)	56 (50%)	0.36
Lactulose dose (ml)	24.5±28.6	27.8±38.2	0.49
Rifaximin	20 (18%)	28 (25%)	0.18
Opioids	24 (21%)	18 (16%)	0.36
Other laxatives	22 (19%)	14 (13%)	0.16
Fiber	10 (9%)	14 (13%)	0.37
Daily bowel movements	2.1±1.2	2.3±1.0	0.67
Outcomes
Stable course of HE medications over 6 months	22 (20%)	37 (32%)	0.04
Future admissions over 6 months	41 (36%)	5 (4%)	<0.0001
Future HE-related admission over 6 months	14 (12%)	1 (1%)	0.002

BSS: Bristol Stool Scale; HE: hepatic encephalopathy